<DOC>
	<DOCNO>NCT02057913</DOCNO>
	<brief_summary>VinCaP multicentre single-arm phase II trial . 22 patient receive Vinflunine chemotherapy ( Vinflunine 320mg/m2 give intravenously day 1 cycle 21 day , four cycle give prior formal re-staging ) .</brief_summary>
	<brief_title>A Phase II Trial Vinflunine Chemotherapy Locally-advanced Metastatic Carcinoma Penis ( VinCaP )</brief_title>
	<detailed_description />
	<mesh_term>Penile Neoplasms</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Male , ≥18 year . 2 . Measurable disease determine RECIST ( Response Evaluation Criteria Solid Tumors ) criterion ( version 1.1 ) . 3 . Patients present purely cutaneous measurable disease fulfill RECIST Criteria ( see Appendix 1 ) . Lesions minimum size 10 mm measure use caliper clinical examination . 4 . Histologicallyproven squamous cell carcinoma penis . 5 . Stage : M1 , ; M0 , T , N3 ( i.e . involvement deep inguinal pelvic lymph node ) ; M0 , T , N2 ( i.e . involvement multiple bilateral superficial lymph node ) ; M0 , T4 ( tumour invades adjacent structure ) N. Notes : 1 . Patients M0 disease may consider , opinion specialist Multi Disciplinary Team ( MDT ) , deem unlikely benefit surgery curative intent unlikely tolerate combination chemotherapy due comorbidities and/or disease burden . 2 . Patients receive prior radiotherapy nontarget lesion may include . 6 . Pretreatment blood count , haematology biochemistry value within follow acceptable limit : Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm3 , Platelets ≥100,000/mm3 , glomerular filtration rate ( GFR ) ≥60ml/min . GFR assess accord local practice ( recommend technique eGFR use MDRD formula . 7 . Liver function : Patients must ( without presence liver metastasis ) : A prothrombin time &gt; 70 % normal value ( NV ) AND Bilirubin &lt; 1.5xUpper Limit Normal ( ULN ) AND Transaminases &lt; 2.5xULN AND GGT &lt; 5xULN 8 . Performance Status Eastern Cooperative Oncology Group ( ECOG ) 0 , 1 2 . 9 . Written , inform consent . 1 . Pure verrucous carcinoma penis . 2 . Squamous carcinoma urethra . 3 . Patients measurable disease determine RECIST ( version 1.1 ) . 4 . T1 N1 M0 disease . 5 . T2 N1 M0 disease . 6 . M0 , T3 , N1 ( tumour invades urethra prostate single inguinal node involve ) . 7 . Unfit vinflunine chemotherapy ( assessed multidisciplinary team ) . 8 . Previous chemotherapy chemoradiotherapy . 9 . Contraindication chemotherapy . 10 . Other malignancy ( Squamous Cell Carcinoma Basal Cell Carcinoma nonpenile skin ) require surgical nonsurgical treatment last 5 year . All patient previous cancer diagnosis must discuss Chief Investigator prior entry trial . 11 . Patients receive radiotherapy target lesion lesion act target lesion instead : e.g . Patients recurrent pelvic lymph node deem irresectable prior radiotherapy lymph node : i. INELIGIBLE involve lymph node site disease . ii . ELIGIBLE measurable site disease e.g . pulmonary metastasis . If uncertain , please discuss Chief Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Penile neoplasm</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Vinflunine</keyword>
	<keyword>Phase II</keyword>
</DOC>